http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
정두용,강동혁,정해도,이주용,김도경,하지수,전진형(Jin Hyung Jeon),조강수 대한비뇨의학회 2023 Investigative and Clinical Urology Vol.64 No.3
The oncologic outcomes of cytoreductive prostatectomy (CRP) in oligometastatic prostate cancer (OmPCa) are still controversial. Therefore, we conducted a systematic review and meta-analysis on the oncologic outcome of CRP in OmPCa. OVID-Medline, OVID-Embase, and Cochrane Library databases were searched to identify eligible studies published before January 2023. A total of 11 studies (929 patients), 1 randomized controlled trial (RCT) and 10 non-RCT studies, were included in the final analysis. RCT and non-RCT were further analyzed separately. End points were progression-free-survival (PFS), time to castration-resistant prostate cancer (CRPCa), cancer-specific-survival (CSS) and overall-survival (OS). It was analyzed using hazard ratio (HR) and 95% confidence intervals (CIs). In PFS, in RCT, HR=0.43 (CIs=0.27–0.69) was shown statistically significant, but in non-RCTs, HR=0.50 (CIs=0.20–1.25), there was no statistical difference. And, in time to CRPCa was statistically significant in the CRP group in all analyses (RCT; HR=0.44; CIs=0.29–0.67) (non-RCTs; HR=0.64; CIs=0.47–0.88). Next, CSS was not statistically different between the two groups (HR=0.63; CIs=0.37–1.05). Finally, OS showed better results in the CRP group in all analyses (RCT; HR=0.44; CIs=0.26–0.76) (non-RCTs; HR=0.59; CIs=0.37–0.93). Patients who received CRP in OmPCa showed better oncologic outcomes compared to controls. Notably, time to CRPC and OS showed significantly improved compared with control. We recommend that experienced urologists who are capable of managing complications consider CRP as a strategy to achieve good oncological outcomes in OmPCa. However, since most of the included studies are non-RCT studies, caution should be exercised in interpreting the results.
정두용,최종현,승경록,최경남,김민철,이태의 대한산부인과학회 1995 Obstetrics & Gynecology Science Vol.38 No.1
저자 등은 위가 원발병소로서 양측 난소에 전이된 Kukenberg 종양 1예를 경험하였기에 문 헌고찰과 함께 보고하는 바이다. Kukenberg tumor of ovary almost metastasize from gastrointestinal tract and it is very rare. We experienced on case of ovarian tumor that presented of kukenberg tumor metastasis from the stomach. therefore, we report this case with a brief review of the literature of kukenberg tumor.
Feasibility and Efficacy of Intermediate-Supine Percutaneous Nephrolithotomy: Initial Experience
정두용,이주영,Kyu Hyun Kim,최재혁,조강수 전남대학교 의과학연구소 2014 전남의대학술지 Vol.50 No.2
We evaluated the feasibility and efficacy of intermediate-supine percutaneous nephrolithotomy(PCNL) in patients with renal calculi. Fifteen patients were included inthis study. The intermediate-supine operative position was modified by using a 1-L salinebag below the ipsilateral upper flank. A nephrostomy and stone extraction wereperformed as usual. After completion of the stone removal, a nephrostomy tube wasused when necessary according to the surgeon’s decision. If there was no significantbleeding or renal pelvic injury, tubeless PCNL was performed. The mean stone sizewas 5.48±5.69 cm2, the mean operative time was 78.93±38.72 minutes, and the meanhospital stay was 2.60±1.29 days. Tubeless PCNL was performed in 13 cases (86.7%),and retrograde procedures were simultaneously performed without a change of positionin 2 patients (ureteroscopic ureterolithotomy in one patient and transurethralplacement of an occlusion catheter in one patient). There were two complications accordingto the Clavien-Dindo classification (Grade I in one patient and Grade II in onepatient). The success rate was 80.0% and the complete stone-free rate was 73.3%. Threepatients with a significant remnant stone were also successfully managed with additionalprocedures (one patient underwent a second-look operation, and the remainingtwo patients were treated with shock wave lithotripsy). In the treatment of renal calculi,intermediate-supine PCNL may be a safe and effective choice that offers several advantageswith excellent outcomes. Thus, a prospective study with a larger population isneeded to verify our outcomes.
정두용,홍창희,임영재,이용승,김상운,한상원 대한비뇨의학회 2015 Investigative and Clinical Urology Vol.56 No.2
Purpose: To evaluate changes in differential renal function (DRF), as a functional outcome, in children who underwent redo pyeloplastyfor management of failed pyeloplasty and to examine the factors that affect functional outcomes. Materials and Methods: Between January 2002 and November 2010, a total of 18 patients who underwent redo pyeloplasty forpersistent ureteropelvic junction obstruction after failed pyeloplasty were enrolled in this study. We assessed perioperative factorsand evaluated changes in renal cortical thickness (RCT), renal function, and hydronephrosis by use of serial ultrasound and diureticrenography. Results: The mean follow-up period was 44.83±28.86 months. After redo pyeloplasty, prevention of further functional deteriorationwas observed in only 12 of the 18 patients. After dividing the patients according to this observation, we discovered significantdifferences in both change in DRF (dDRF) and change in RCT (dRCT) (difference between before and after initial pyeloplasty)between the two groups (p<0.001). Additionally, we noted a significant positive correlation between dRCT and dDRF. All patientsshowed improvements in hydronephrosis grade and relief of symptoms compared with before redo pyeloplasty. Conclusions: Redo pyeloplasty should be considered in cases of failed pyeloplasty to preserve renal function and obtain relieffrom symptoms. If patients show severe deterioration of DRF or a decrease in RCT after initial pyeloplasty, preservation of DRF inthese patients after redo pyeloplasty could be difficult. Therefore, redo pyeloplasty should be performed before severe deteriorationof DRF or decrease in RCT.